Comprehensive Epilepsy Program marks 100th responsive neurostimulation procedure

• April 8, 2026

Oral Shigella Vaccine Hits 89% Efficacy in Challenge Trial

An investigational oral Shigella sonnei vaccine showed robust protection against shigellosis in a phase 2 controlled human infection trial.

• by Teraya Smith

• July 23, 2026

• 3 min

Skin Deep Survival

Peptidomics via LC-MS/MS links early skin immune maturation to recovery from chytrid fungus in common midwife toads  

• July 23, 2026

• 3 min

GRAPPA, EULAR Criteria May Identify Complex PsA

Application of newly proposed GRAPPA and EULAR criteria in a longitudinal cohort identified progressively smaller groups of patients with early psoriatic arthritis who experienced persistently worse patient-reported outcomes.

• by Andrea Surnit

• July 23, 2026

• 3 min